CU23472A1 - Péptido antagonista de la interleucina-15 - Google Patents

Péptido antagonista de la interleucina-15

Info

Publication number
CU23472A1
CU23472A1 CU20040198A CU20040198A CU23472A1 CU 23472 A1 CU23472 A1 CU 23472A1 CU 20040198 A CU20040198 A CU 20040198A CU 20040198 A CU20040198 A CU 20040198A CU 23472 A1 CU23472 A1 CU 23472A1
Authority
CU
Cuba
Prior art keywords
peptide
interleucine
antagonist peptide
relates
present
Prior art date
Application number
CU20040198A
Other languages
English (en)
Inventor
Agueero Celia Aurora Arrieta
Rico Ania Cabrales
Rodriguez Silvio Ernesto Perea
Perez Haydee Geronimo
Acosta Osvaldo Reyes
Savio Alicia Santos
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20040198A priority Critical patent/CU23472A1/es
Priority to ARP050103835A priority patent/AR051924A1/es
Priority to KR1020077008676A priority patent/KR101254113B1/ko
Priority to RU2007114288/04A priority patent/RU2396276C2/ru
Priority to AU2005284529A priority patent/AU2005284529C1/en
Priority to BRPI0515403A priority patent/BRPI0515403B8/pt
Priority to US11/662,844 priority patent/US7736638B2/en
Priority to AT05779505T priority patent/ATE434623T1/de
Priority to CA2579798A priority patent/CA2579798C/en
Priority to JP2007531575A priority patent/JP4750795B2/ja
Priority to ES05779505T priority patent/ES2328717T3/es
Priority to DE602005015131T priority patent/DE602005015131D1/de
Priority to PT05779505T priority patent/PT1801119E/pt
Priority to EP05779505A priority patent/EP1801119B1/en
Priority to PCT/CU2005/000007 priority patent/WO2006029578A1/es
Priority to MX2007002996A priority patent/MX2007002996A/es
Priority to CN2005800342690A priority patent/CN101120015B/zh
Priority to ZA200702128A priority patent/ZA200702128B/xx
Publication of CU23472A1 publication Critical patent/CU23472A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se relaciona con la rama de la farmacología molecular en particular con un péptido perteneciente a la secuencia de la Interleucina - 15 (IL - 15), que es capaz de inhibir la actividad biológica de esta molécula; análogos o miméticos de dicho péptido. En la presente invención se muestra que el péptido al unirse a la subunidad alfa del receptor (IL - 15Ra) inhibe la proliferación de células T inducida por la IL - 15 y la apoptosis mediada por TNFa. La invención se relaciona además con el uso del péptido en el tratamiento de patologías donde la expresión anormal de la IL - 15 o IL - 15Ra esta relacionada con el curso de la enfermedad.
CU20040198A 2004-09-17 2004-09-17 Péptido antagonista de la interleucina-15 CU23472A1 (es)

Priority Applications (18)

Application Number Priority Date Filing Date Title
CU20040198A CU23472A1 (es) 2004-09-17 2004-09-17 Péptido antagonista de la interleucina-15
ARP050103835A AR051924A1 (es) 2004-09-17 2005-09-14 Peptido antagonista de la interleucina -15
KR1020077008676A KR101254113B1 (ko) 2004-09-17 2005-09-16 인터류이킨―15 안타고니스트 펩티드
RU2007114288/04A RU2396276C2 (ru) 2004-09-17 2005-09-16 Пептидный антагонист интерлейкина-15
AU2005284529A AU2005284529C1 (en) 2004-09-17 2005-09-16 Interleukin-15 antagonist peptide
BRPI0515403A BRPI0515403B8 (pt) 2004-09-17 2005-09-16 formulação farmacêutica capaz de inibir a atividade biológica da il-15, e, formulação de vacina
US11/662,844 US7736638B2 (en) 2004-09-17 2005-09-16 Interleukin-15 antagonist peptide
AT05779505T ATE434623T1 (de) 2004-09-17 2005-09-16 Interleukin-15-antagonistisches peptid
CA2579798A CA2579798C (en) 2004-09-17 2005-09-16 Interleukin-15 antagonist peptide
JP2007531575A JP4750795B2 (ja) 2004-09-17 2005-09-16 インターロイキン−１５アンタゴニストペプチド
ES05779505T ES2328717T3 (es) 2004-09-17 2005-09-16 Peptido antagonista de interleuquina-15.
DE602005015131T DE602005015131D1 (de) 2004-09-17 2005-09-16 Interleukin-15-antagonistisches peptid
PT05779505T PT1801119E (pt) 2004-09-17 2005-09-16 Peptídeo antagonista de interleuquina-15
EP05779505A EP1801119B1 (en) 2004-09-17 2005-09-16 Interleukin-15 antagonist peptide
PCT/CU2005/000007 WO2006029578A1 (es) 2004-09-17 2005-09-16 Péptido antagonista de la interleucina-15
MX2007002996A MX2007002996A (es) 2004-09-17 2005-09-16 Peptido antagonista de la interleucina-15.
CN2005800342690A CN101120015B (zh) 2004-09-17 2005-09-16 白介素-15拮抗剂肽
ZA200702128A ZA200702128B (en) 2004-09-17 2007-03-13 Interleukin-15 antagonist peptide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20040198A CU23472A1 (es) 2004-09-17 2004-09-17 Péptido antagonista de la interleucina-15

Publications (1)

Publication Number Publication Date
CU23472A1 true CU23472A1 (es) 2009-12-17

Family

ID=40262834

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20040198A CU23472A1 (es) 2004-09-17 2004-09-17 Péptido antagonista de la interleucina-15

Country Status (18)

Country Link
US (1) US7736638B2 (es)
EP (1) EP1801119B1 (es)
JP (1) JP4750795B2 (es)
KR (1) KR101254113B1 (es)
CN (1) CN101120015B (es)
AR (1) AR051924A1 (es)
AT (1) ATE434623T1 (es)
AU (1) AU2005284529C1 (es)
BR (1) BRPI0515403B8 (es)
CA (1) CA2579798C (es)
CU (1) CU23472A1 (es)
DE (1) DE602005015131D1 (es)
ES (1) ES2328717T3 (es)
MX (1) MX2007002996A (es)
PT (1) PT1801119E (es)
RU (1) RU2396276C2 (es)
WO (1) WO2006029578A1 (es)
ZA (1) ZA200702128B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23716A1 (es) * 2008-09-30 2011-10-05 Ct Ingenieria Genetica Biotech Péptido antagonista de la actividad de la interleucina-15
CN101831435B (zh) * 2010-05-10 2013-09-11 昆山贝瑞康生物科技有限公司 小鼠il-15亚型蛋白的制备及其应用
CA2824515C (en) 2011-01-18 2022-09-13 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
PL404138A1 (pl) 2013-05-31 2014-12-08 Warszawski Uniwersytet Medyczny Pochodne kwasu benzoesowego jako inhibitory receptora IL-15Rα
PL404174A1 (pl) 2013-05-31 2014-12-08 Warszawski Uniwersytet Medyczny Zastosowanie pochodnych aminowych jako inhibitorów aktywności interleukiny 15
PL405506A1 (pl) 2013-09-30 2015-04-13 Warszawski Uniwersytet Medyczny Zastosowanie pochodnej kwasu 7-aminocefalosporanowego jako inhibitora aktywności biologicznej IL-15 i IL-2
PL405505A1 (pl) 2013-09-30 2015-04-13 Warszawski Uniwersytet Medyczny Zastosowanie pochodnej kwasu diaminodikarboksylowego jako inhibitora aktywności biologicznej IL-15 I IL-2
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
EP3093295B1 (en) * 2014-01-08 2020-05-27 Shanghai Hengrui Pharmaceutical Co., Ltd. Il-15 heterogeneous dimer protein and uses thereof
WO2016105575A1 (en) * 2014-12-23 2016-06-30 Siemens Healthcare Diagnostics Inc. Proteolytic digestion of cardiac troponin i
ES2950399T3 (es) * 2015-04-13 2023-10-09 Regeneron Pharma Ratones humanizados Sirpa-IL15 insertados y métodos de uso de los mismos
EP3978512A1 (en) 2015-10-09 2022-04-06 Bioniz, LLC Modulating gamma-c-cytokine activity
MX2019004327A (es) 2016-10-14 2019-10-14 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
KR102707650B1 (ko) 2017-04-07 2024-09-19 바이오니즈 테라퓨틱스, 아이엔씨. 감마-c-사이토카인 활성의 안정한 조절자
AU2018257917B2 (en) 2017-04-24 2023-05-04 University Of Massachusetts Diagnosis and treatment of vitiligo
KR101954214B1 (ko) * 2017-05-23 2019-03-06 (주)케어젠 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
CU24545B1 (es) 2017-12-29 2021-09-07 Ct Ingenieria Genetica Biotecnologia Péptido antagonista de la actividad de la interleucina-15
KR20210003814A (ko) 2018-04-18 2021-01-12 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
WO2019204646A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
CA3097593A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
CA3097625A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
CA3116188A1 (en) 2018-10-12 2020-04-16 Xencor, Inc. Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
US11618776B2 (en) 2018-12-20 2023-04-04 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
BR112021021878A2 (pt) 2019-05-03 2022-01-18 Bioniz Llc Modulação dos efeitos de sinalização da gama-c-citocina para tratamento da alopecia e distúrbios associados
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
KR20250044344A (ko) 2022-08-04 2025-03-31 노파르티스 파르마 아게 아토피 피부염의 치료에 유용한 il-15 저해제

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
WO1995027722A1 (en) 1994-04-06 1995-10-19 Immunex Corporation Interleukin-15
MX9606537A (es) * 1994-07-05 1997-12-31 Steeno Res Group As Inmunomoduladores.
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
JP2001502521A (ja) * 1996-04-26 2001-02-27 ベス イスラエル デアコネス メディカル センター インターロイキン―１５の拮抗剤
EP0849583A1 (en) * 1996-12-12 1998-06-24 European Community Split Hopkinson bar testing apparatus
EP0971728B1 (en) * 1997-02-21 2002-12-11 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Use of interleukin-15
GB9814892D0 (en) 1998-07-10 1998-09-09 Kennedy Rheumatology Inst Treatment of celiac disease
AU6689700A (en) * 1999-07-06 2001-01-22 Silvia Bulfone-Paus Method of treating psoriasis with il-15 antagonist
US7247304B2 (en) * 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
CU23093A1 (es) * 2002-10-09 2005-10-19 Ct Ingenieria Genetica Biotech Composición vacunal que comprende interleucina-15 (il-15)
ES2367027T3 (es) 2004-02-27 2011-10-27 Inserm (Institut National De La Santé Et De La Recherche Medicale) Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista.

Also Published As

Publication number Publication date
ZA200702128B (en) 2008-08-27
KR20070072876A (ko) 2007-07-06
WO2006029578A1 (es) 2006-03-23
KR101254113B1 (ko) 2013-04-15
JP4750795B2 (ja) 2011-08-17
ATE434623T1 (de) 2009-07-15
CA2579798C (en) 2012-08-21
BRPI0515403B1 (pt) 2019-03-26
JP2008512994A (ja) 2008-05-01
RU2396276C2 (ru) 2010-08-10
CN101120015B (zh) 2011-05-25
CA2579798A1 (en) 2006-03-23
PT1801119E (pt) 2009-09-21
BRPI0515403A (pt) 2008-07-22
EP1801119B1 (en) 2009-06-24
CN101120015A (zh) 2008-02-06
AU2005284529A1 (en) 2006-03-23
MX2007002996A (es) 2007-05-16
US7736638B2 (en) 2010-06-15
DE602005015131D1 (de) 2009-08-06
RU2007114288A (ru) 2008-10-27
EP1801119A1 (en) 2007-06-27
AU2005284529B2 (en) 2010-11-25
AR051924A1 (es) 2007-02-21
ES2328717T3 (es) 2009-11-17
BRPI0515403B8 (pt) 2021-05-25
AU2005284529C1 (en) 2011-07-07
US20090136511A1 (en) 2009-05-28

Similar Documents

Publication Publication Date Title
AR051924A1 (es) Peptido antagonista de la interleucina -15
AR064032A1 (es) Usos terapeuticos de polipeptidos heterologos il-17a/f
DOP2006000025A (es) Agonistas de pyy y sus usos
SV2011003880A (es) Anticuerpos humanos de alta afinidad para el receptor il-4 humano
CL2008002140A1 (es) Compuestos derivados de azaindol, inhibidores jak; composicion farmaceutica que los comprende; y su uso en el tratamiento de trastornos proliferativos, cardiacos, neurodegenerativo, asociados con trasplante de organos, artritis reumatoidea, entre otras.
EA201290557A1 (ru) Пептидный аналог оксинтомодулина
EP2142849A4 (en) LED LIGHTING DEVICE WITH EXTREMELY UNIFORM LIGHTING PATTERN
UY31602A1 (es) Formas cristalinas del dimetoxi-docetaxel y sus procedimientos de preparación
UY32665A (es) Proteinas de union al antigeno
CR9312A (es) Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer
AR051524A1 (es) Seleccion de pacientes para una terapia con un inhibidor de her
ECSP088221A (es) Agonistas adrenoreceptores alfa2c
CL2010001346A1 (es) Polipeptido mutante del factor de crecimiento de fibroblastos (fgf); multimero que comprende dos o mas copias del polipeptido de fusion antes mencionado; composicion farmaceutica que comprende el polipeptido.
CL2009001099A1 (es) Uso de una muteina de interleuquina-2 humana para el tratamiento y/o prevencion de una enfermedad autoinmune.
HN2007006799A (es) Analogos de biaril piperazinil-piridina sustituidos
CY1122051T1 (el) Φαρμακευτικοι συνδυασμοι που περιλαμβανουν τεστοστερονη και ταδαλαφιλη για την θεραπεια της γυναικειας σεξουαλικης δυσλειτουργιας
ES2530670T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
NO20082345L (no) Selektive VPAC2 reseptorpeptidagonister
CL2007002890A1 (es) Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad.
UY28650A1 (es) Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta
PL1988914T3 (pl) Kombinacja analogów somatostatyny o różnej selektywności wobec podtypów ludzkich receptorów somatostatyny
EP2370109A4 (en) PROLIFERATION ASSOCIATED MODULATION OF SPLITTING OF INTEGRIN ALPHA 6 ISOFORMS
ATE389670T1 (de) Selektive peptidische agonisten des vpac2- rezeptors
CO2021013687A2 (es) Variantes de interleucina-2 (il2) y receptor de interleucina-2 (il2r) para la activación específica de células efectoras inmunitarias
PA8776101A1 (es) Actividad antitumoral de cci-779 en el carcinoma papilar de celulas renales